OUR

PORTFOLIO

Verity focuses on specialty pharmaceuticals that are well entrenched in treatment protocols and in demand by physicians, for their patients.

 

 

VERITY-BCG™ | Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I

Product Monograph

Patient Information

 

Healthcare professionals can access additional information about VERITY-BCG™ by visiting www.verity‑bcg.com.

 

AN IMPORTANT MESSAGE FROM VERITY

With the extremely upsetting Russian invasion of Ukraine, we would like to inform you that the product VERITY-BCG™ does not have any connection to Russia, outside of the name of the strain which is used for historical reference only. VERITY-BCG™ is manufactured by the world’s largest manufacturer of vaccines, the Serum Institute of India. Furthermore, the entirety of the supply chain of VERITY-BCG™ does not have any link whatsoever with Russia. Verity Pharmaceuticals finds the Russian invasion and war atrocities within Ukraine, abhorrent and our support lies with the citizens and country of Ukraine.

ZeulideDepot® ™ Leuprolide acetate for depot suspension Acétate de leuprolide pour suspension à effet prolongé

Product Monograph

Patient Information

 

Healthcare professionals can access additional information about ZeulideDepot® by visiting www.zeulidedepot.com.

IVOZFO™ | fosfomycin for injection | fosfomycine pour injection

Product Monograph

Patient Information

 

Healthcare professionals can access additional information about IVOZFO™ by visiting www.ivozfo.com.

 

Partnered Brands

 

BRINAVESS

Product Monograph

 

Access additional information about BRINAVESS™ by visiting www.cipherpharma.com.

AGGRASTAT

Product Monograph

 

Access additional information about AGGRASTAT™ by visiting www.cipherpharma.com.

 

New Opportunities

Verity Pharmaceuticals is actively negotiating with global pharmaceutical companies on in-licensing targeted agents that our Scientific Advisory Board have identified as therapeutically relevant and in therapeutic areas where similar agents are in short supply or are at risk of being in short supply in the Canadian market.

We are currently exploring opportunities in the following therapeutic areas:

  • Fertility
  • Genitourinary
  • Infectious Disease
  • Oncology